Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 20,606 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Genitourinary System Clear all
Terminated Phase 4 Interventional Results available

Postmenopausal Pessary Users: Estrogen Versus Trimosan

NCT03943823
View directory record Official record
Conditions
Vaginosis, Vaginosis, Bacterial, Vaginal Discharge
Interventions
Estrogen vaginal cream, Trimo-San vaginal gel
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Phase 1Phase 2 Interventional

Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

NCT01020396
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
37
States / cities
Huntsville, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 4, 2026, 4:16 AM EDT
Recruiting Not applicable Interventional

Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery

NCT02706561
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
questionnaires, three in-person sessions, monthly phone calls, Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED), Enhanced Monitoring and Education (EME)
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Phase 4 Interventional

Diuretics and Volume Overload in Early CKD

NCT05171686
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 4:16 AM EDT
Active, not recruiting No phase listed Observational

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

NCT05424783
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate
Other
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 76 Years · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Not applicable Interventional

Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

NCT00002066
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Annandale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 4:16 AM EDT
Active, not recruiting No phase listed Observational

Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

NCT03728842
View directory record Official record
Conditions
Melanoma; Renal Cell Carcinoma
Interventions
Blood collection for laboratory studies, Data collection from medical record
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Phase 2 Interventional

OGX-427 in Castration Resistant Prostate Cancer Patients

NCT01120470
View directory record Official record
Conditions
Castration Resistant Prostate Cancer
Interventions
OGX-427, Prednisone
Drug
Lead sponsor
British Columbia Cancer Agency
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Venglustat in Patients With Renal Impairment

NCT03687554
View directory record Official record
Conditions
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Interventions
Venglustat GZ/SAR402671
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

NCT04572854
View directory record Official record
Conditions
C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Phase 2 Interventional Results available

Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00114166
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
78
States / cities
Hartford, Connecticut • New Britain, Connecticut • Lewes, Delaware + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 4, 2026, 4:16 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

NCT03428802
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

NCT00141037
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Thalidomide to Treat Oral Lesions in HIV-Infected Patients

NCT00001524
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome, HIV Infection
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Phase 3 Interventional Results available

Trichomonas Vaginalis Repeat Infections Among HIV Negative Women

NCT01832480
View directory record Official record
Conditions
Vaginitis Trichomonal or Due to Trichomonas
Interventions
MTZ 500 mg twice daily x 7 days, MTZ 2 g
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
18 Years and older · Female only
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Not applicable Interventional Results available

Home Semen Testing in Men Beginning Attempts to Conceive

NCT05503862
View directory record Official record
Conditions
Male Infertility
Interventions
YoSperm
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 4, 2026, 4:16 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Preventing Health Damaging Behaviors in Male and Female Army Recruits

NCT01234103
View directory record Official record
Conditions
Sexually Transmitted Infection (STI) Prevention, Unintended Pregnancy Prevention, Sexual Risk Reduction, Alcohol and Other Substance Use Prevention, Intimate Partner Violence Prevention
Interventions
Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits
Behavioral
Lead sponsor
United States Department of Defense
Federal
Eligibility
18 Years and older
Enrollment
933 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 4, 2026, 4:16 AM EDT
Not listed Not applicable Interventional

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

NCT01017627
View directory record Official record
Conditions
Anemia, Mortality
Interventions
Early anemia diagnosis and treatment, No change from normal routine
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Denver, Colorado • Jacksonville, Florida • Chicago, Illinois + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 4, 2026, 4:16 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor

NCT00306462
View directory record Official record
Conditions
Premature Birth, Premature Labor
Interventions
Magnesium sulfate, Oral Nifedipine or placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2009 · Synced Oct 4, 2026, 4:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men

NCT01447186
View directory record Official record
Conditions
Prostate Cancer, Cancer
Interventions
Post-Test Questionnaire, Interviews, Focus Groups
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
45 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 4, 2026, 4:16 AM EDT
Withdrawn Phase 2 Interventional

Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer

NCT01409473
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate SBRT with concurrent boost to intraprostatic lesion(s)
Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Littleton, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Not applicable Interventional

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

NCT00002341
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Not applicable Interventional Results available

Optimizing Electronic Alerts for Acute Kidney Injury

NCT02753751
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
AKI Alert
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 4, 2026, 4:16 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

NCT00004929
View directory record Official record
Conditions
Prostate Cancer
Interventions
MUC-2-KLH vaccine, QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 4, 2026, 4:16 AM EDT